Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort. / Egeberg, Alexander; Schlapbach, Christoph; Haugaard, Jeanette Halskou; Nymand, Lea; Thein, David; Thomsen, Simon Francis; Thyssen, Jacob P.

I: JAAD International, Bind 14, 2024, s. 77-83.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Egeberg, A, Schlapbach, C, Haugaard, JH, Nymand, L, Thein, D, Thomsen, SF & Thyssen, JP 2024, 'Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort', JAAD International, bind 14, s. 77-83. https://doi.org/10.1016/j.jdin.2023.11.004

APA

Egeberg, A., Schlapbach, C., Haugaard, J. H., Nymand, L., Thein, D., Thomsen, S. F., & Thyssen, J. P. (2024). Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort. JAAD International, 14, 77-83. https://doi.org/10.1016/j.jdin.2023.11.004

Vancouver

Egeberg A, Schlapbach C, Haugaard JH, Nymand L, Thein D, Thomsen SF o.a. Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort. JAAD International. 2024;14:77-83. https://doi.org/10.1016/j.jdin.2023.11.004

Author

Egeberg, Alexander ; Schlapbach, Christoph ; Haugaard, Jeanette Halskou ; Nymand, Lea ; Thein, David ; Thomsen, Simon Francis ; Thyssen, Jacob P. / Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort. I: JAAD International. 2024 ; Bind 14. s. 77-83.

Bibtex

@article{c49a7cdf102646beb034870dd2e1b719,
title = "Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort",
abstract = "Background: Topical corticosteroids (TCS) are used to treat most patients with chronic hand eczema (CHE), but knowledge about TCS-related adverse events in CHE is limited. Objectives: To investigate patient-reported adverse events to TCS in CHE patients. Methods: Data on adverse events related to TCS use in patients with CHE were analyzed from the Danish Skin Cohort; a prospective survey of a hospital cohort. We assessed patients{\textquoteright} knowledge about TCS use and adverse event risks, and preference of TCS versus a nonsteroidal topical alternative. Results: Of 724 adults with CHE (64.0% women; mean age 57.5 [standard deviation 12.8] years), 64.1% reported skin atrophy, 41.4% cracks/fissures, 23.9% bleeding, 45.9% pain/stinging sensation, 40.0% reduced hand dexterity, and 40.2% worsening of CHE signs or symptoms from using TCS. We observed CHE-severity-dependent associations (all groups; P <.0001). Most patients (76.4%) would prefer a nonsteroidal option, 10.9% were neutral/indifferent, and 12.7% would prefer TCS for CHE. The median numerical rating scale-score (ranging from 0 to 10) was 10 (interquartile range 6-10) for preferring a nonsteroidal topical treatment. Limitations: Differences across TCS formulations were unexplored. Conclusion: TCS-related cutaneous adverse events were common. There is a desire from patients for novel steroid-free topical alternatives for CHE treatment.",
keywords = "adverse events, chronic hand eczema, Danish Skin Cohort, side effects, topical corticosteroids",
author = "Alexander Egeberg and Christoph Schlapbach and Haugaard, {Jeanette Halskou} and Lea Nymand and David Thein and Thomsen, {Simon Francis} and Thyssen, {Jacob P.}",
note = "Publisher Copyright: {\textcopyright} 2023 American Academy of Dermatology, Inc.",
year = "2024",
doi = "10.1016/j.jdin.2023.11.004",
language = "English",
volume = "14",
pages = "77--83",
journal = "JAAD International",
issn = "2666-3287",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Adverse events from topical corticosteroid use in chronic hand eczema — Findings from the Danish Skin Cohort

AU - Egeberg, Alexander

AU - Schlapbach, Christoph

AU - Haugaard, Jeanette Halskou

AU - Nymand, Lea

AU - Thein, David

AU - Thomsen, Simon Francis

AU - Thyssen, Jacob P.

N1 - Publisher Copyright: © 2023 American Academy of Dermatology, Inc.

PY - 2024

Y1 - 2024

N2 - Background: Topical corticosteroids (TCS) are used to treat most patients with chronic hand eczema (CHE), but knowledge about TCS-related adverse events in CHE is limited. Objectives: To investigate patient-reported adverse events to TCS in CHE patients. Methods: Data on adverse events related to TCS use in patients with CHE were analyzed from the Danish Skin Cohort; a prospective survey of a hospital cohort. We assessed patients’ knowledge about TCS use and adverse event risks, and preference of TCS versus a nonsteroidal topical alternative. Results: Of 724 adults with CHE (64.0% women; mean age 57.5 [standard deviation 12.8] years), 64.1% reported skin atrophy, 41.4% cracks/fissures, 23.9% bleeding, 45.9% pain/stinging sensation, 40.0% reduced hand dexterity, and 40.2% worsening of CHE signs or symptoms from using TCS. We observed CHE-severity-dependent associations (all groups; P <.0001). Most patients (76.4%) would prefer a nonsteroidal option, 10.9% were neutral/indifferent, and 12.7% would prefer TCS for CHE. The median numerical rating scale-score (ranging from 0 to 10) was 10 (interquartile range 6-10) for preferring a nonsteroidal topical treatment. Limitations: Differences across TCS formulations were unexplored. Conclusion: TCS-related cutaneous adverse events were common. There is a desire from patients for novel steroid-free topical alternatives for CHE treatment.

AB - Background: Topical corticosteroids (TCS) are used to treat most patients with chronic hand eczema (CHE), but knowledge about TCS-related adverse events in CHE is limited. Objectives: To investigate patient-reported adverse events to TCS in CHE patients. Methods: Data on adverse events related to TCS use in patients with CHE were analyzed from the Danish Skin Cohort; a prospective survey of a hospital cohort. We assessed patients’ knowledge about TCS use and adverse event risks, and preference of TCS versus a nonsteroidal topical alternative. Results: Of 724 adults with CHE (64.0% women; mean age 57.5 [standard deviation 12.8] years), 64.1% reported skin atrophy, 41.4% cracks/fissures, 23.9% bleeding, 45.9% pain/stinging sensation, 40.0% reduced hand dexterity, and 40.2% worsening of CHE signs or symptoms from using TCS. We observed CHE-severity-dependent associations (all groups; P <.0001). Most patients (76.4%) would prefer a nonsteroidal option, 10.9% were neutral/indifferent, and 12.7% would prefer TCS for CHE. The median numerical rating scale-score (ranging from 0 to 10) was 10 (interquartile range 6-10) for preferring a nonsteroidal topical treatment. Limitations: Differences across TCS formulations were unexplored. Conclusion: TCS-related cutaneous adverse events were common. There is a desire from patients for novel steroid-free topical alternatives for CHE treatment.

KW - adverse events

KW - chronic hand eczema

KW - Danish Skin Cohort

KW - side effects

KW - topical corticosteroids

U2 - 10.1016/j.jdin.2023.11.004

DO - 10.1016/j.jdin.2023.11.004

M3 - Journal article

C2 - 38274394

AN - SCOPUS:85181828746

VL - 14

SP - 77

EP - 83

JO - JAAD International

JF - JAAD International

SN - 2666-3287

ER -

ID: 379654315